Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 113

1.

Antipsychotic drug-like facilitation of latent inhibition by a brain-penetrating neurotensin-1 receptor agonist.

Feifel D, Shilling PD, Fazlinejad AA, Melendez G.

J Psychopharmacol. 2016 Jan 18. pii: 0269881115625360. [Epub ahead of print]

PMID:
26783230
2.

Effects of intranasal oxytocin on neural processing within a socially relevant neural circuit.

Singh F, Nunag J, Muldoon G, Cadenhead KS, Pineda JA, Feifel D.

Eur Neuropsychopharmacol. 2015 Dec 17. pii: S0924-977X(15)00409-5. doi: 10.1016/j.euroneuro.2015.12.026. [Epub ahead of print]

PMID:
26727038
3.

Oxytocin modulates meta-mood as a function of age and sex.

Ebner NC, Horta M, Lin T, Feifel D, Fischer H, Cohen RA.

Front Aging Neurosci. 2015 Sep 10;7:175. doi: 10.3389/fnagi.2015.00175. eCollection 2015.

4.

A Review of Oxytocin's Effects on the Positive, Negative, and Cognitive Domains of Schizophrenia.

Feifel D, Shilling PD, MacDonald K.

Biol Psychiatry. 2016 Feb 1;79(3):222-33. doi: 10.1016/j.biopsych.2015.07.025. Epub 2015 Aug 13. Review.

PMID:
26410353
5.

Efficacy and Safety of Low-field Synchronized Transcranial Magnetic Stimulation (sTMS) for Treatment of Major Depression.

Leuchter AF, Cook IA, Feifel D, Goethe JW, Husain M, Carpenter LL, Thase ME, Krystal AD, Philip NS, Bhati MT, Burke WJ, Howland RH, Sheline YI, Aaronson ST, Iosifescu DV, O'Reardon JP, Gilmer WS, Jain R, Burgoyne KS, Phillips B, Manberg PJ, Massaro J, Hunter AM, Lisanby SH, George MS.

Brain Stimul. 2015 Jul-Aug;8(4):787-94. doi: 10.1016/j.brs.2015.05.005. Epub 2015 May 22.

PMID:
26143022
6.

Intranasal oxytocin administration prior to exposure therapy for arachnophobia impedes treatment response.

Acheson DT, Feifel D, Kamenski M, Mckinney R, Risbrough VB.

Depress Anxiety. 2015 Jun;32(6):400-7. doi: 10.1002/da.22362. Epub 2015 Mar 31.

PMID:
25826649
7.

Peripherally administered oxytocin modulates latent inhibition in a manner consistent with antipsychotic drugs.

Feifel D, Shilling PD, Hillman J, Maisel M, Winfield J, Melendez G.

Behav Brain Res. 2015 Feb 1;278:424-8. doi: 10.1016/j.bbr.2014.10.023. Epub 2014 Oct 30.

8.

Systemic administration of the neurotensin NTS₁-receptor agonist PD149163 improves performance on a memory task in naturally deficient male brown Norway rats.

Keiser AA, Matazel KS, Esser MK, Feifel D, Prus AJ.

Exp Clin Psychopharmacol. 2014 Dec;22(6):541-7. doi: 10.1037/a0037912. Epub 2014 Sep 15.

9.

Oxytocin's role in anxiety: a critical appraisal.

MacDonald K, Feifel D.

Brain Res. 2014 Sep 11;1580:22-56. doi: 10.1016/j.brainres.2014.01.025. Epub 2014 Jan 24. Review.

PMID:
24468203
10.

Developing Research Domain Criteria (RDoC) to improve diagnosis and treatment of social deficits in psychiatric disorders: the Mirror Neuron System as a model.

Singh F, Feifel D.

Schizophr Res. 2013 Dec;151(1-3):293-4. doi: 10.1016/j.schres.2013.09.014. Epub 2013 Oct 4. No abstract available.

PMID:
24094678
11.

Intramuscular ziprasidone: influence of alcohol and benzodiazepines on vital signs in the emergency setting.

Wilson MP, MacDonald K, Vilke GM, Ronquillo L, Feifel D.

J Emerg Med. 2013 Dec;45(6):901-8. doi: 10.1016/j.jemermed.2013.07.020. Epub 2013 Sep 24.

PMID:
24071032
12.

Assessment of attention in male and female Brattleboro rats using a self-paced five-choice serial reaction time task.

Berquist Ii MD, Mooney-Leber SM, Feifel D, Prus AJ.

Brain Res. 2013 Nov 6;1537:174-9. doi: 10.1016/j.brainres.2013.09.012. Epub 2013 Sep 18.

PMID:
24055104
13.

Not disappointed by anxiety: a reply to Cardoso and Ellenbogen's commentary "Oxytocin and psychotherapy: keeping context and person in mind".

MacDonald K, Feifel D, Brüne M, Lamb K, Wilson MP, Golshan S, MacDonald T.

Psychoneuroendocrinology. 2013 Dec;38(12):3173-5. doi: 10.1016/j.psyneuen.2013.08.003. Epub 2013 Sep 12. No abstract available.

PMID:
24035602
14.

Limited evidence that benzodiazepines are beneficial in the treatment of disturbed behaviour.

Feifel D.

Evid Based Ment Health. 2013 Nov;16(4):111. doi: 10.1136/eb-2013-101432. Epub 2013 Aug 16. No abstract available.

PMID:
23956251
15.

In reply:.

Feifel D, Wilson MP, Pepper D, Currier GW, Holloman G.

West J Emerg Med. 2012 Dec;13(6):536-7. doi: 10.5811/westjem.2012.7.12773. No abstract available.

16.

Oxytocin and psychotherapy: a pilot study of its physiological, behavioral and subjective effects in males with depression.

MacDonald K, MacDonald TM, Brüne M, Lamb K, Wilson MP, Golshan S, Feifel D.

Psychoneuroendocrinology. 2013 Dec;38(12):2831-43. doi: 10.1016/j.psyneuen.2013.05.014. Epub 2013 Jun 28.

PMID:
23810433
17.

The effect of intranasal oxytocin treatment on conditioned fear extinction and recall in a healthy human sample.

Acheson D, Feifel D, de Wilde S, McKinney R, Lohr J, Risbrough V.

Psychopharmacology (Berl). 2013 Sep;229(1):199-208. doi: 10.1007/s00213-013-3099-4. Epub 2013 May 5.

PMID:
23644911
18.

Helping oxytocin deliver: considerations in the development of oxytocin-based therapeutics for brain disorders.

Macdonald K, Feifel D.

Front Neurosci. 2013 Mar 15;7:35. doi: 10.3389/fnins.2013.00035. eCollection 2013.

19.

Oxytocin in schizophrenia: a review of evidence for its therapeutic effects.

Macdonald K, Feifel D.

Acta Neuropsychiatr. 2012 Jun 1;24(3):130-146. Epub 2011 Dec 19.

20.

Adjunctive intranasal oxytocin improves verbal memory in people with schizophrenia.

Feifel D, Macdonald K, Cobb P, Minassian A.

Schizophr Res. 2012 Aug;139(1-3):207-10. doi: 10.1016/j.schres.2012.05.018. Epub 2012 Jun 8.

PMID:
22682705
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk